BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

215 related articles for article (PubMed ID: 31003763)

  • 1. Directly observed hepatitis C treatment with opioid substitution therapy in community pharmacies: A qualitative study.
    Gunn J; Higgs P
    Res Social Adm Pharm; 2020 Sep; 16(9):1298-1301. PubMed ID: 31003763
    [TBL] [Abstract][Full Text] [Related]  

  • 2.
    Byrne C; Radley A; Inglis SK; Beer LJZ; Palmer N; Pham MD; Healy B; Doyle JS; Donnan P; Dillon JF
    BMJ Open; 2020 Aug; 10(8):e036501. PubMed ID: 32868356
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Direct-acting Antivirals for Chronic Hepatitis C Virus Infection in People Who Inject Drugs or Receive Opioid Substitution Therapy: A Systematic Review and Meta-analysis.
    Graf C; Mücke MM; Dultz G; Peiffer KH; Kubesch A; Ingiliz P; Zeuzem S; Herrmann E; Vermehren J
    Clin Infect Dis; 2020 May; 70(11):2355-2365. PubMed ID: 31513710
    [TBL] [Abstract][Full Text] [Related]  

  • 4. "I want to get better, but…": identifying the perceptions and experiences of people who inject drugs with respect to evolving hepatitis C virus treatments.
    Goodyear T; Brown H; Browne AJ; Hoong P; Ti L; Knight R
    Int J Equity Health; 2021 Mar; 20(1):81. PubMed ID: 33740984
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Potential Reach of Opioid Substitution Settings to Deliver HCV Care to People Who Inject Drugs in Australia.
    Butler K; Day C; Dietze P; Bruno R; Alati R; Burns L
    J Subst Abuse Treat; 2015 Nov; 58():90-4. PubMed ID: 26117080
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DOT-C: A cluster randomised feasibility trial evaluating directly observed anti-HCV therapy in a population receiving opioid substitute therapy from community pharmacy.
    Radley A; Tait J; Dillon JF
    Int J Drug Policy; 2017 Sep; 47():126-136. PubMed ID: 28647161
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical effectiveness of pharmacist-led versus conventionally delivered antiviral treatment for hepatitis C virus in patients receiving opioid substitution therapy: a pragmatic, cluster-randomised trial.
    Radley A; de Bruin M; Inglis SK; Donnan PT; Hapca A; Barclay ST; Fraser A; Dillon JF
    Lancet Gastroenterol Hepatol; 2020 Sep; 5(9):809-818. PubMed ID: 32526210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical effectiveness of pharmacy-led versus conventionally delivered antiviral treatment for hepatitis C in patients receiving opioid substitution therapy: a study protocol for a pragmatic cluster randomised trial.
    Radley A; de Bruin M; Inglis SK; Donnan PT; Dillon JF
    BMJ Open; 2018 Dec; 8(12):e021443. PubMed ID: 30552244
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive Models of Hepatitis C Care for People Who Inject Drugs Receiving Opioid Agonist Therapy: A Randomized Controlled Trial.
    Akiyama MJ; Norton BL; Arnsten JH; Agyemang L; Heo M; Litwin AH
    Ann Intern Med; 2019 May; 170(9):594-603. PubMed ID: 30959528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. 'Treat my whole person, not just my condition': qualitative explorations of hepatitis C care delivery preferences among people who inject drugs.
    Tsui JI; Barry MP; Austin EJ; Sweek EW; Tung E; Hansen RN; Ninburg M; Scott JD; Glick SN; Williams EC
    Addict Sci Clin Pract; 2021 Aug; 16(1):52. PubMed ID: 34384494
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Model projections on the impact of HCV treatment in the prevention of HCV transmission among people who inject drugs in Europe.
    Fraser H; Martin NK; Brummer-Korvenkontio H; Carrieri P; Dalgard O; Dillon J; Goldberg D; Hutchinson S; Jauffret-Roustide M; Kåberg M; Matser AA; Matičič M; Midgard H; Mravcik V; Øvrehus A; Prins M; Reimer J; Robaeys G; Schulte B; van Santen DK; Zimmermann R; Vickerman P; Hickman M
    J Hepatol; 2018 Mar; 68(3):402-411. PubMed ID: 29080808
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Directly observed therapy for HCV with glecaprevir/pibrentasvir alongside opioid substitution in people who inject drugs-First real world data from Austria.
    Schmidbauer C; Schubert R; Schütz A; Schwanke C; Luhn J; Gutic E; Pirker R; Lang T; Reiberger T; Haltmayer H; Gschwantler M
    PLoS One; 2020; 15(3):e0229239. PubMed ID: 32155165
    [TBL] [Abstract][Full Text] [Related]  

  • 13. "Everybody living with a chronic disease is entitled to be cured": Challenges and opportunities in scaling up access to direct-acting antiviral hepatitis C virus treatment among people who inject drugs.
    Goodyear T; Ti L; Carrieri P; Small W; Knight R
    Int J Drug Policy; 2020 Jul; 81():102766. PubMed ID: 32416525
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A Video-Observed Treatment Strategy to Improve Adherence to Treatment Among Persons Who Inject Drugs Infected With Hepatitis C Virus: Qualitative Study of Stakeholder Perceptions and Experiences.
    Karasz A; Merchant K; Arnsten J; Feinberg J; Kim AY; Lum PJ; McKee MD; Mehta SH; Meissner P; Norton BL; Page K; Pericot-Valverde I; Singh R; Stein E; Taylor LE; Tsui JI; Wagner K; Litwin A
    J Med Internet Res; 2023 Jun; 25():e38176. PubMed ID: 37266986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combination interventions to prevent HCV transmission among people who inject drugs: modeling the impact of antiviral treatment, needle and syringe programs, and opiate substitution therapy.
    Martin NK; Hickman M; Hutchinson SJ; Goldberg DJ; Vickerman P
    Clin Infect Dis; 2013 Aug; 57 Suppl 2(Suppl 2):S39-45. PubMed ID: 23884064
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Uptake of direct acting antiviral therapies for the treatment of hepatitis C virus among people who inject drugs in a universal health-care system.
    Butler K; Larney S; Day CA; Burns L
    Drug Alcohol Rev; 2019 Mar; 38(3):264-269. PubMed ID: 30548702
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Modelling the impact of incarceration and prison-based hepatitis C virus (HCV) treatment on HCV transmission among people who inject drugs in Scotland.
    Stone J; Martin NK; Hickman M; Hutchinson SJ; Aspinall E; Taylor A; Munro A; Dunleavy K; Peters E; Bramley P; Hayes PC; Goldberg DJ; Vickerman P
    Addiction; 2017 Jul; 112(7):1302-1314. PubMed ID: 28257600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Direct-acting antiviral agents for HCV infection affecting people who inject drugs.
    Grebely J; Hajarizadeh B; Dore GJ
    Nat Rev Gastroenterol Hepatol; 2017 Nov; 14(11):641-651. PubMed ID: 28831184
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Life projects: the transformative potential of direct-acting antiviral treatment for hepatitis C among people who inject drugs.
    E Williams B; Nelons D; Seaman A; Witkowska M; Ronan W; Wheelock H; Zaman A; Garcia J
    Int J Drug Policy; 2019 Oct; 72():138-145. PubMed ID: 30995968
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Elimination of HCV as a public health concern among people who inject drugs by 2030 - What will it take to get there?
    Grebely J; Dore GJ; Morin S; Rockstroh JK; Klein MB
    J Int AIDS Soc; 2017 Jul; 20(1):22146. PubMed ID: 28782335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.